PACKAGE LEAFLET: INFORMATION FOR THE USER
Ibufarmalid 600 mg oral suspension
Ibuprofen (D.O.E.)
Read all of this leaflet carefully before you start taking this medicine.
|
This leaflet tells you about:
Ibuprofen belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).
This medicine is indicated for the treatment of fever, pain of mild or moderate intensity in processes such as dental pain, post-surgical pain, headache including migraine, symptomatic relief of pain, fever, and inflammation that accompanies processes such as pharyngitis (inflammation of the upper throat), tonsillitis (inflammation of the tonsils), and otitis (inflammation of certain structures of the middle ear), among others, treatment of arthritis or joint inflammation (rheumatoid, psoriatic, gouty, etc.), osteoarthritis (inflammation of the cartilage of the joints), ankylosing spondylitis (inflammation affecting the joints of the spine), non-rheumatic inflammation (bursitis, synovitis, capsulitis, or other types of inflammatory injuries of traumatic or sports origin), and primary dysmenorrhea (painful menstruation).
It is important to use the smallest dose that relieves-controls the pain and do not take this medicine Ibufarmalid 600 mg oral suspension for longer than necessary to control your symptoms.
Do not take Ibufarmalid 600 mg oral suspension if:
Be careful with Ibufarmalid 600 mg oral suspension:
Tell your doctor:
Infections
Ibufarmalid may hide the signs of an infection, such as fever and pain. Therefore, it is possible that Ibufarmalid may delay the appropriate treatment of the infection, which may increase the risk of complications. This has been observed in bacterial pneumonia and bacterial skin infections related to chickenpox. If you take this medicine while having an infection and the symptoms of the infection persist or worsen, consult a doctor without delay.
Cardiovascular Precautions
Medicines like Ibufarmalid 600 mg oral suspension may be associated with a moderate increase in the risk of suffering heart attacks ("myocardial infarctions") or strokes. This risk is more likely to occur when high doses and prolonged treatments are used. Do not exceed the recommended dose or treatment duration.
If you have heart problems, a history of strokes, or think you may be at risk for these conditions (for example, you have high blood pressure, suffer from diabetes, have high cholesterol, or are a smoker), you should consult your doctor or pharmacist about this treatment.
Also, this type of medicine may cause fluid retention, especially in patients with heart failure and/or high blood pressure (hypertension).
Skin Reactions
Severe skin reactions have been reported with Ibufarmalid 600 mg oral suspension treatment. Stop taking Ibufarmalid 600 mg oral suspension and see a doctor immediately if you experience any skin rash, lesions on the mucous membranes, blisters, or other signs of allergy, as these may be the first signs of a severe skin reaction. See section 4.
Taking Ibufarmalid 600 mg oral suspension with food and drinks:
You can take it alone or with food. In general, it is recommended to take it before meals to reduce the possibility of stomach upset.
Pregnancy, breastfeeding, and fertility
Pregnancy:
Consult your doctor or pharmacist before using any medicine.
Do not take Ibufarmalid 600 mg oral suspension if you are in the last 3 months of pregnancy, as it may harm the fetus or cause problems during delivery. It may cause kidney and heart problems in your fetus. It may affect your and your baby's tendency to bleed and delay or prolong labor more than expected. Do not take this medicine during the first 6 months of pregnancy unless it is clearly necessary and as indicated by your doctor. If you need treatment during this period or while trying to become pregnant, you should take the minimum dose for the shortest possible time. From the 20th week of pregnancy, Ibufarmalid 600 mg oral suspension may cause kidney problems in your fetus if taken for more than a few days, which may cause low levels of amniotic fluid surrounding the baby (oligohydramnios) or narrowing of a blood vessel (ductus arteriosus) in the baby's heart. If you need treatment for more than a few days, your doctor may recommend additional checks.
Because the administration of medicines of the Ibufarmalid 600 mg oral suspension type has been associated with an increased risk of congenital anomalies/abortions, it is not recommended to administer it during the first and second trimester of pregnancy unless it is strictly necessary. In these cases, the dose and duration will be limited to the minimum possible.
Fertility:
For patients of childbearing age, it should be noted that medicines of the Ibufarmalid 600 mg oral suspension type have been associated with a decrease in fertility.
Breastfeeding:
Although the levels of the medicine in breast milk are negligible, it is recommended to consult a doctor in cases of long-term treatment or high doses during breastfeeding.
Use in children:
Do not administer to children under 12 years old without consulting a doctor.
Driving and using machines:
If you experience dizziness, vertigo, vision changes, or other symptoms while taking this medicine, you should not drive or use machinery. If you only take one dose of ibuprofen or for a short period, it is not necessary to take special precautions.
Use of other medicines:
Tell your doctor or pharmacist if you are using or have recently used any other medicine, even those bought without a prescription, as it may be necessary to interrupt treatment or adjust the dose of one of them.
It is not recommended to take ibuprofen with:
Other interactions that require caution:
Information about some of the components of Ibufarmalid 600 mg oral suspension
As it contains azorubine as an excipient, it may cause allergic reactions. It may cause asthma, especially in patients allergic to aspirin.
Each sachet contains 87 mg of sodium, which should be taken into account in patients with low-sodium diets.
Follow these instructions unless your doctor has given you different instructions.
This medicine is administered orally.
Use the lowest effective dose for the shortest necessary time to relieve symptoms. If you have an infection, consult your doctor without delay if the symptoms (such as fever and pain) persist or worsen (see section 2).
The recommended dose in adults and young people from 12 to 18 years old is one sachet (600 mg) every 6 to 8 hours, depending on the intensity of the condition and the response to treatment. In adults, the maximum recommended daily dose is 2400 mg, while in young people from 12 to 18 years old, it is 1800 mg.
Do not administer Ibufarmalid 600 mg oral suspension to children under 12 years old without consulting a doctor.
If you are over 60 years old, your doctor may prescribe a lower dose than usual. If so, the dose should only be increased once your doctor has checked that you tolerate the medicine well.
If you have kidney or liver disease, your doctor may prescribe a lower dose than usual. If so, take the exact dose that your doctor has prescribed.
Always take the lowest effective dose. The duration of treatment will be decided by your doctor and should not be stopped before.
This product is a suspension. It should be homogenized before taking by pressing the top and bottom of the sachet with your fingers several times. It can be taken directly from the sachet or diluted in water.
In case of gastrointestinal upset, it is recommended to take the medicine with food.
Remember to take your medicine, and if you think the effect of Ibufarmalid 600 mg oral suspension is too strong or too weak, tell your doctor or pharmacist.
If you take more Ibufarmalid 600 mg oral suspension than you should:
If you have taken more Ibufarmalid 600 mg oral suspension than you should, or if a child has accidentally ingested the medicine, consult a doctor or the Toxicology Information Service (telephone: 91 562 04 20) immediately, indicating the medicine and the amount ingested, or go to the nearest hospital to find out about the risk and ask for advice on the measures to be taken. It is recommended to take the package and the leaflet of the medicine to the healthcare professional.
The symptoms of overdose may include nausea, stomach pain, vomiting (which may contain blood), headache, ringing in the ears, confusion, and involuntary eye movement. At high doses, symptoms such as drowsiness, chest pain, palpitations, loss of consciousness, convulsions (mainly in children), weakness, and dizziness, blood in the urine, low potassium levels in the blood, chills, and breathing problems have been reported.
The most frequent symptoms in case of overdose are: nausea, vomiting, abdominal pain, headache, vertigo, drowsiness, involuntary eye movements, blurred vision, ringing in the ears, and sometimes low blood pressure and fainting.
If you forget to take Ibufarmalid 600 mg oral suspension:
Do not take a double dose to make up for forgotten doses.
If you forget to take your corresponding dose, take it as soon as you remember. However, if the time for the next dose is near, skip the forgotten dose and take the next dose at the usual time.
Like all medicines, Ibufarmalid 600 mg oral suspension may have adverse effects.
Chest pain, which may be a sign of a potentially serious allergic reaction called Kounis syndrome.
The following adverse effects have been observed:
Gastrointestinal:
The most frequent adverse effects that occur with medicines like Ibufarmalid 600 mg oral suspension are gastrointestinal: peptic ulcers, digestive hemorrhages, perforations (in some cases fatal), especially in the elderly. Nausea, vomiting, diarrhea, flatulence, constipation, heartburn, abdominal pain, blood in stools, oral thrush, worsening of ulcerative colitis and Crohn's disease have also been observed. Less frequently, the appearance of gastritis has been observed.
Frequent:nausea, vomiting, abdominal pain, heartburn, flatulence, and constipation.
Infrequent:hemorrhage, stomach or duodenal ulcers.
Rare:gastric or intestinal perforation, esophageal inflammation, and ulcers or inflammation of the intestine.
Skin and allergic reactions:
Frequent:skin rash.
Infrequent:skin redness, itching or skin swelling, lip, face, or tongue swelling, increased nasal secretion, and difficulty breathing.
Rare:severe allergic reactions (anaphylactic shock)
Very rare:intense itching of the skin with sudden onset or blisters on the skin, joint pain, and fever (systemic lupus erythematosus), hair loss, skin reactions due to light influence,
Medicines like Ibufarmalid 600 mg oral suspension may be associated, in very rare cases, with severe blistering reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and allergic vasculitis.
Aseptic meningitis (inflammation of the membranes that cover the brain and spinal cord), in most cases in patients with some autoimmune disease such as systemic lupus erythematosus.
Severe allergic reaction that can manifest with nausea, vomiting, swelling of the face, tongue, and throat, difficulty breathing, asthma, palpitations, hypotension, or shock.
Frequency "not known":A severe skin reaction known as DRESS syndrome may occur. The symptoms of DRESS syndrome include: skin rash, lymph node inflammation, and elevated eosinophils (a type of white blood cell). A generalized red scaly rash, with bumps under the skin and localized blisters, mainly on the skin folds, trunk, and upper limbs, accompanied by fever at the start of treatment (acute generalized exanthematous pustulosis), may also occur. Stop taking Ibufarmalid 600 mg oral suspension if you experience these symptoms and seek medical attention immediately. See also section 2. The skin becomes sensitive to light.
Central nervous system:
Frequent:headache, feeling of instability, and nervousness.
Infrequent:fatigue or drowsiness, insomnia, anxiety, vision changes, ringing or buzzing in the ears.
Rare:disorientation or confusion, depression, abnormal or blurred vision, and hearing difficulty.
Very rare:aseptic meningitis.
Blood:
Very rare:prolonged bleeding time, alterations in blood cells (the first symptoms may be: fever, sore throat, mouth ulcers, flu-like symptoms, excessive fatigue, nasal and skin bleeding)
Cardiovascular:
Medicines like Ibufarmalid 600 mg oral suspension may be associated with a moderate increased risk of suffering a heart attack ("myocardial infarction") or stroke
Edema (fluid retention), arterial hypertension, and heart failure have also been observed in association with treatments with medicines of the type Ibufarmalid 600 mg oral suspension
Kidney:
Kidney disease.
Liver:
Rare:hepatitis (inflammation of the liver) and jaundice (yellowing of the skin) Medicines like Ibufarmalid 600 mg oral suspension may be associated, in rare cases, with liver damage
If you observe these adverse effects or any other not described in this prospectus, consult your doctor or pharmacist
Keep Ibufarmalid 600 mg oral suspension out of the reach and sight of children.
Keep it in its original packaging.
Expiration:
Do not use Ibufarmalid 600 mg oral suspension after the expiration date indicated on the packaging.
The expiration date is the last day of the month indicated
Medicines should not be thrown away through the sewers or in the trash. Ask your pharmacist how to dispose of the packaging and medicines that you no longer need. This way, you will help protect the environment.
Composition
The active ingredient is Ibuprofen. Each sachet contains 600 mg of ibuprofen.
The other components (excipients) are: sodium benzoate (E-211), anhydrous citric acid, sodium citrate, sodium saccharin, sodium chloride, hypromellose, xanthan gum, liquid maltitol, thaumatin (E-957), strawberry flavor, azorubine (E-122), glycerol, and purified water.
Appearance of the Product and Packaging Content
Ibufarmalid 600 mg oral suspension is presented in the form of an oral suspension to be taken directly from the sachet or dissolved in water. Each package contains 20 or 40 sachets.
Marketing Authorization Holder
Laboratorios Farmalider, S.A. C/Aragoneses, nº 2 28108 Alcobendas (Madrid) Spain
Manufacturer
Industrial Farmacéutica Cantabria, S.A. Carretera Cazoña/Adarzo s/n 39011 Santander Spain
Date of the Last Revision of this Prospectus:November 2024
Detailed and updated information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/